Real-world study: pegcetacoplan slowed GA growth by 41% over 2 years

A retrospective case series followed 77 eyes from 58 patients with geographic atrophy secondary to age-related macular degeneration treated with intravitreal pegcetacoplan for 2 years, averaging 18 injections per eye. The study reported a 41% reduction in square-root GA growth rate compared to pre-treatment rates (0.19 vs 0.33 mm/year, p<0.001), with most eyes showing stable or further-decreased growth rates in year two; mean best-corrected visual acuity declined from 63 to 55 letters over 2 years (p<0.001).

Most relevant for: Patients with geographic atrophy secondary to age-related macular degeneration undergoing long-term intravitreal complement inhibitor therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.